Posted by Michael Wonder on 21 Apr 2026
First FDA approved treatment for patients with focal segmental glomerulosclerosis—a rare kidney condition
16 April 2026 - The US FDA on Monday approved a new indication for Filspari (sparsentan) tablets for reducing proteinuria in patients aged eight years and older with focal segmental glomerulosclerosis without nephrotic syndrome.
This approval marks an important milestone because it provides the first FDA approved treatment for patients living with this rare kidney condition.
